A temporary increase in payments from Medicare for physician-administered biosimilars is designed to further boost their uptake. The increase went into effect on October 3rd. It’s one of the lesser-known drug pricing provisions contained in the Inflation Reduction Act.
Inflation Reduction Act Provision Aims To Further Spur Biosimilar Uptake With Temporary Add-On Payment In Medicare Part B
